Mirtazapine - Merck & Co
Alternative Names: Avanza; Azamianserin; ME-2040; Mepirzapin; Norset; ORG-3770; Promyrtil; Reflex; REFLEX Org3770; Remergil; Remergon; Remeron; RemeronSolTab; Rexer; ZispinLatest Information Update: 05 Nov 2023
At a glance
- Originator Organon
- Developer Meiji Seika Pharma; Merck & Co
- Class Dibenzazepines; Tetracyclic antidepressants
- Mechanism of Action Alpha 2 adrenergic receptor antagonists; Serotonin 3 receptor antagonists; Serotonin 5-HT2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Major depressive disorder
- Phase II Fibromyalgia
Most Recent Events
- 12 Nov 2018 Mirtazapine is still in phase II trials for Fibromyalgia in Japan (Meiji Seika Pharma pipeline, November 2018)
- 01 Oct 2015 Phase-II development is ongoing for Fibromyalgia in Japan (PO) (Meiji Seika Pharma pipeline, October 2015)
- 31 Oct 2014 Meiji Seika Pharma completes a phase II trial in Fibromyalgia in Japan (JapicCTI-122005)